Search Results 381-390 of 18024 for Alopecia

1. A Study to Evaluate the Optune® (Tumor Treating Fields) Concomitant with RT & TMZ to Treat Newly-diagnosed Glioblastoma - Mayo Clinic

   CTC grade 4 non-hematological Toxicity (except for alopecia, nausea, vomiting);; Significant liver function impairment - AST or ALT > 3 times the upper limit ...

2. Estradiol in Treating Patients With ER Beta Positive, Triple Negative Locally Advanced or Metastatic Breast Cancer - Mayo Clinic

   *Note: Any adverse events derived from these therapies must be ≤ Grade 2 prior to starting study therapy (exception: alopecia). Participating Mayo Clinic ...

3. Duvelisib and Nivolumab for the Treatment of Stage IIB-IVB Mycosis Fungoides and Sezary Syndrome - Mayo Clinic

   ... alopecia and neuropathy - Patients who are receiving any other investigational agents - History of allergic reactions attributed to compounds of similar ...

4. A Study Of The Pan-KRAS Inhibitor LY4066434 In Participants With KRAS Mutant Solid Tumors - Mayo Clinic

   ... alopecia, peripheral neuropathy and ongoing endocrinopathies controlled on appropriate replacement therapy * Have significant cardiovascular disease defined ...

5. Randomized, Double-blind Study Comparing Tremelimumab to Placebo in Subjects With Unresectable Malignant Mesothelioma - Mayo Clinic

   Any unresolved toxicity NCI CTCAE Grade ≥ 2 from previous anticancer therapy; with the exception of vitiligo and alopecia. Participating Mayo Clinic ...

6. Erlotinib Hydrochloride and Cabozantinib-s-Malate Alone or In Combination as Second or Third Line Therapy in Treating Patients With Stage IV Non-Small Cell Lung Cancer - Mayo Clinic

   ... alopecia and other non-clinically significant adverse events (AEs); Patients with no known brain metastasis at baseline must have baseline brain imaging ...

7. Crizotinib in Treating Patients with Stage IB-IIIA Non-small Cell Lung Cancer that has been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial) - Mayo Clinic

   ... alopecia and the criteria outlined; Patients must not have any history of cancer within 5 years from randomization, with the exception of in-situ carcinomas ...

8. Publications - Elizabeth J. Cathcart-Rake, M.D. - Mayo Clinic

   ... alopecia in breast cancer patients. Support Care Cancer. 2023 Nov 22; 31 (12):717. View PubMed; Cathcart-Rake EJ, Tevaarwerk AJ, Haddad TC, D'Andre SD, Ruddy ...

9. Alendronate and cholecalciferol (oral route) - Side effects & dosage - Mayo Clinic

   Alendronate and cholecalciferol combination is used to treat osteoporosis (thinning of the bone) in women after menopause. This medicine may also be used to ...

10. A Study to Evaluate Effectiveness and Safety of Deucravacitinib (BMS-986165) Compared With Placebo in Participants With Active Systemic Lupus Erythematosus - Mayo Clinic

    * Lupus headache, alopecia, organic brain syndrome, and mucosal ulcers must be recorded on SLEDAI 2K, if indicated, but do not count toward the points ...